• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

Recent Advances in Protamine Sulfate (98001-69-5) Research: Applications and Innovations

Protamine sulfate (CAS: 98001-69-5) is a well-known pharmaceutical agent primarily used to reverse the anticoagulant effects of heparin. Recent studies have expanded its applications, revealing novel roles in drug delivery, tissue engineering, and biotechnology. This research brief synthesizes the latest findings on protamine sulfate, focusing on its chemical properties, mechanisms of action, and emerging therapeutic uses. The compound's unique polycationic nature, derived from its high arginine content, continues to inspire innovative research across multiple disciplines.

A 2023 study published in the Journal of Controlled Release demonstrated protamine sulfate's efficacy in enhancing the delivery of nucleic acid therapeutics. Researchers utilized its cationic properties to form stable complexes with siRNA, improving cellular uptake and target specificity. The study reported a 60% increase in gene silencing efficiency compared to standard lipid-based carriers, highlighting protamine sulfate's potential as a cost-effective alternative for gene therapy formulations. These findings are particularly relevant for rare genetic disorders where precise delivery systems are critical.

In the field of regenerative medicine, protamine sulfate has shown promise as a scaffold modifier. A recent Biomaterials Science publication detailed its incorporation into hydrogels for cartilage repair. The compound's ability to interact with glycosaminoglycans enhanced mechanical properties while maintaining biocompatibility. Animal models exhibited 40% faster tissue regeneration compared to controls, suggesting protamine sulfate's utility in orthopedic applications. This builds upon earlier work demonstrating its antimicrobial properties, which may reduce infection risks in implantable devices.

The pharmaceutical industry has also explored protamine sulfate's role in vaccine development. A 2024 preclinical trial reported in Vaccine utilized protamine sulfate as an adjuvant in mRNA vaccine formulations. The compound improved antigen presentation by dendritic cells, resulting in stronger and more durable immune responses. Notably, the formulation maintained stability at elevated temperatures, addressing a key challenge in vaccine distribution. These advances position protamine sulfate as a versatile component in next-generation vaccine platforms.

Quality control and standardization remain active research areas for protamine sulfate. Recent analytical chemistry studies have developed advanced HPLC methods to quantify batch-to-batch variability, addressing regulatory concerns about consistency in pharmaceutical preparations. The European Pharmacopoeia's 2024 updates include stricter specifications for protamine sulfate purity, reflecting these methodological improvements. Such developments ensure the compound's continued safe use in clinical settings while supporting its expansion into novel applications.

Looking forward, researchers are investigating protamine sulfate's potential in cancer therapeutics. Early-stage studies suggest its polycationic structure may enhance tumor penetration of chemotherapeutic agents while reducing systemic toxicity. A 2024 Nature Communications paper described a protamine sulfate-modified nanoparticle system that achieved 75% tumor regression in murine models, with significantly reduced off-target effects. These findings underscore the compound's versatility and the importance of continued research into its molecular interactions and therapeutic optimization.

• 13813-19-9(Sulfuric acid-d2)
• 133-92-6(Kanamycin Sulfate)
• 7446-33-5(Yttrium(III) sulfate octahydrate)
• 7783-20-2(Ammonium sulfate)
• 13814-01-2(Ammonium-d8 Sulfate)
• 43086-58-4(Ammonium sulphate,≥99.0%,AR-)
• 9012-00-4(Protamines)
• 13701-70-7(Sulfuric acid,vanadium(3+) salt (3:2))
• 7778-80-5(Potassium Sulphate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)